Armin Khayatian traces his focus on mental health investing back to his family's experience as refugees from Iran, where PTSD was common, and he brings direct experience from five years at Compass Pathways, including leading special projects for the CEO and serving as Director of Business and Corporate Development as the company scaled psilocybin development. He looks at psychedelic medicine with a practical, business-minded eye—thinking about trials, regulation, manufacturing, and reimbursement rather than just the science—and stays calm about short-term stock swings, pointing to Warren Buffett's idea that markets vote in the short run but weigh value over time.